MaxCyte, Inc. (MXCT)

Market Cap	165.24M
Revenue (ttm)	35.75M
Net Income (ttm)	-44.77M
Shares Out	106.61M
EPS (ttm)	-0.42
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	585,307
Open	1.680
Previous Close	1.650
Day's Range	1.550 - 1.686
52-Week Range	1.260 - 5.200
Beta	0.27
Analysts	Buy
Price Target	7.50 (+383.87%)
Earnings Date	Nov 5, 2025

About MXCT

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineer...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jul 30, 2021
• Employees: 114
• Stock Exchange: NASDAQ
• Ticker Symbol: MXCT
• Website: https://www.maxcyte.com

Financial Performance

In 2024, MaxCyte's revenue was $38.63 million, a decrease of -6.44% compared to the previous year's $41.29 million. Losses were -$41.06 million, 8.26% more than in 2023.

Analyst Summary

According to 4 analysts, the average rating for MXCT stock is "Buy." The 12-month stock price target is $7.5, which is an increase of 383.87% from the latest price.

Price Target

$7.5

(383.87% upside)

Analyst Consensus: Buy